Impax Laboratories Inc (IPXL.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|66||Independent Chairman of the Board|
|56||2017||President, Chief Executive Officer, Director|
|49||2012||Chief Financial Officer, Senior Vice President - Finance|
|53||2016||President - Generics Division|
|64||2008||President - Impax Specialty Pharmaceutical Division|
- BRIEF-Maverick Capita Ltd Reports 9.9 pct Passive Stake In Impax Laboratories As Of Dec 31, 2017
- BRIEF-Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets
- BRIEF-Corepharma Acquired By Investor Group
- BRIEF-Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace Cream
- BRIEF-Impax Announces Sale Of Taiwan Manufacturing Facility